Short Term Investments - Dizal Jiangsu Pharmaceutical Co Ltd (SSE:688192) - Alpha Spread
D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 33.4 CNY -7.2% Market Closed
Market Cap: 13.6B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dizal Jiangsu Pharmaceutical Co Ltd
Short-Term Investments Peer Comparison

Comparables:
6160
1801
9926
603392
300122

Competitive Short-Term Investments Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Short-Term Investments
ÂĄ678.7m
CAGR 3-Years
96%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Short-Term Investments
ÂĄ7.5B
CAGR 3-Years
-32%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Short-Term Investments
ÂĄ7.4B
CAGR 3-Years
3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Short-Term Investments
ÂĄ195.9m
CAGR 3-Years
21%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Short-Term Investments
ÂĄ2.5B
CAGR 3-Years
188%
CAGR 5-Years
506%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Short-Term Investments?
Short-Term Investments
678.7m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Short-Term Investments amounts to 678.7m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Short-Term Investments growth rate?
Short-Term Investments CAGR 5Y
26%

Over the last year, the Short-Term Investments growth was -48%. The average annual Short-Term Investments growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 96% over the past three years , 26% over the past five years .

Back to Top